448965-31-9

Basic information

• Product Name: 3-benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzofuran-2-ylmethyl ester
• Synonyms: 3-benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzofuran-2-ylmethyl ester
• CAS NO: 448965-31-9
• Molecular Weight: 446.483
• Mol File: 448965-31-9.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 3-benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzofuran-2-ylmethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 3-benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzofuran-2-ylmethyl ester(448965-31-9)
• EPA Substance Registry System: 3-benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid benzofuran-2-ylmethyl ester(448965-31-9)

Safety Data

• Hazardous Substances Data: 448965-31-9(Hazardous Substances Data)

Upstream product

• 55038-01-2 benzofuran-2-yl-methanol 
• 448964-87-2 3-benzyl-1-methyl-2,4-dioxo-1,2,3,4-tetrahydro-thieno[2,3-d]pyrimidine-6-carboxylic acid 

Relevant articles and documents

Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib

This invention provides a combination, comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with celecoxib, or a pharmaceutically acceptable salt thereof, or valdecoxib, or a pharmaceutically acceptable salt thereof. This invention also provides a method of treating a disease that is responsive to inhibition of MMP-13 and cyclooxygenase-2, comprising administering to a patient suffering from such a disease the invention combination comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with celecoxib, or a pharmaceutically acceptable salt thereof, or valdecoxib, or a pharmaceutically acceptable salt thereof. This invention also provides a pharmaceutical composition, comprising the invention combination comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with celecoxib, or a pharmaceutically acceptable salt thereof, or valdecoxib, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient. The invention combination may also be further combined with other pharmaceutical agents depending on the disease being treated.

FUSED PYRIMIDINONE MATRIX METALLOPROTEINASE INHIBITORS

Selective MMP-13 inhibitors are fused pyrimidinones of the formula or a pharmaceutically acceptable salt thereof, wherein: W, together with the carbon atoms to which it is attached, form a 5-membered ring diradical X is O, S, SO, SO2, NR5, or CH 2; B is O or NR5; or A and B are taken together to form--C≡C--; R1, R4, and R 5 are hydrogen, alkyl, alkenyl, alkynyl, (CH2)n aryl, (CH2)n cycloalkyl, C1-C6 alkanoyl, or (CH2)n heteroaryl; R2 and R3 are hydrogen, alkyl, alkenyl, alkynyl CN, NO2, NR 4R5, (CH2)n cycloalkyl, (CH2) n aryl, or (CH2)n heteroaryl; R2 may further be halo; n is an integer of from 0 to 5; and R4 and R5 when taken together with a nitrogen to which they are both attached complete a 3-to 8-membered ring containing carbon atoms and optionally containing O, S, or N, and substituted or unsubstituted; with the proviso that R1 and R3 are not both selected from hydrogen and C1-C6 alkyl.